#None #Clinical Pharmacology #Xtalks Webinar #Oligonucleotide Drugs

Insights into First-in-Human Study Design for Oligonucleotides

The pharmaceutical landscape is rapidly evolving, especially in the realm of oligonucleotide (ON) therapies. These drugs, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), have witnessed remarkable advancements and are increasingly in demand due to their potential in treating various diseases. However, while ONs promise substantial benefits, their complexity necessitates a rigorous approach to clinical trials, particularly first-in-human (FIH) studies.

To delve into this critical topic, Xtalks is organizing a free webinar on May 27, 2026, at 10 AM EDT (4 PM CEST). This event aims to equip early drug developers and healthcare professionals with essential insights regarding the design and execution of FIH studies for oligonucleotide drugs. The webinar will cover various aspects such as pharmacokinetics, pharmacodynamics, and toxicity, which are pivotal in shaping the successful translation of these therapies into clinical use.

The Need for Rigorous Study Design

As the utility of ONs evolves from treating rare conditions to addressing much more prevalent diseases, the necessity for meticulous study designs has become paramount. Advances in conjugation technologies and improved targeting capabilities have reduced the safety risks involved with ON drugs, but establishing safety and efficacy remains a time-consuming endeavor. This is largely due to the extensive FIH trials required to ensure patient safety and to reliably demonstrate initial pharmacodynamic effects.

In the upcoming webinar, experts from ICON, including Dr. Rüdiger Kaspera, Dr. Kamelia Mirdamadi, and Dr. Thijs van Iersel, will share their invaluable experiences in the field. They will discuss the innovative strategies that can be implemented to assess safety during the design of these studies. Topics such as sentinel dosing, dose escalation, follow-up periods, and the evaluation of immunogenicity and potential QT prolongation will be explored in detail.

Key Takeaways from the Webinar

1. Translational Considerations: The significance of understanding pharmacokinetics and pharmacodynamics will be emphasized. Participants will learn how these elements impact the therapeutic effectiveness and safety of ON drugs.
2. Safety Mitigation Strategies: Effective safety evaluation is crucial, especially in the early phases of drug development. Insights on approaches such as sentinel dosing will be shared to enhance patient safety during trials.
3. Speaker Expertise: Attendees will benefit from the expertise of clinical pharmacologists who will offer practical guidance to navigate the complexities of FIH study designs.

This webinar represents a unique opportunity to stay abreast of the latest methodologies in oligonucleotide drug developments. By participating, professionals can enhance their understanding of the challenges and considerations necessary for advancing ON therapies.

Why Attend?

The field of oligonucleotide drugs is not only burgeoning, but it also holds immense promise for revolutionizing treatment methodologies across various diseases. As drug developers and clinicians alike strive to innovate and improve patient outcomes, understanding the intricacies of FIH studies will be critical in ensuring the success of these therapies in clinical settings.

To register for this insightful webinar, visit the Xtalks event page and secure your spot today.

Be part of the conversation that shapes the future of oligonucleotide therapies and learn how to optimize your FIH study designs.

About Xtalks
Xtalks offers a platform dedicated to the life sciences community, providing valuable insights and collaborative resources across the pharmaceutical, biotech, and healthcare sectors. With vast experience in hosting informative events, they are committed to supporting professionals in making informed decisions amidst rapid industry changes. Learn more about Xtalks at their official website.